ChemoCentryx Inc (CCXI)vsInsmed Inc (INSM)
CCXI
ChemoCentryx Inc
$10.17
0.00%
HEALTHCARE · Cap: $3.74B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1527% more annual revenue ($606.42M vs $37.28M). CCXI leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CCXI
Avoid32
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
0.0% earnings growth
0.0% margin — thin
ROE of -47.0% — below average capital efficiency
Negative free cash flow — burning cash
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CCXI
CCXI has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CCXI
The primary concerns for CCXI are EPS Growth, Profit Margin, Return on Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CCXI profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
CCXI carries more volatility with a beta of 1.23 — expect wider price swings.
CCXI is growing revenue faster at 5.5% — sustainability is the question.
CCXI generates stronger free cash flow (-27M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ChemoCentryx Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?